Are there any countermeasures against Rx of hair loss pills?

Restriction of high-risk non-covered drugs and non-inclusion of public prescription laws

Chief Cho Won-joon, "The Ministry of Health and Welfare needs to solve the side effects of non-face-to-face contact such as non-common prescription behavior"

The need to reduce the range of diseases allowed for return patients is also likely to be raised

The Health and Welfare Committee of the National Assembly will start reviewing legislation to institutionalize non-face-to-face treatment, excluding the prescription restriction bill for high-risk non-insured drugs such as hair loss treatment, which is being prepared by Rep.

 

Jeon Hye-sook, and the public e-prescription legislation proposed by Rep.

 

However, in the process of institutionalizing non-face-to-face treatment, the issue of prescription of high-risk non-reimbursed drugs and the need for regulatory and management measures for electronic prescriptions to be issued after non-face-to-face treatment are expected to be discussed together.

 

Whether the Ministry of Health and Welfare can clearly come up with measures to solve the problem of abnormal prescriptions and dispensing that can be mass-produced when non-face-to-face treatment is enacted, or the collapse of the healthcare ecosystem such as hospitals, clinics, and pharmacies, will determine the legislative success or failure.

 

On the 24th, the Welfare Committee began reviewing five previously proposed amendments to the Medical Act related to the institutionalization of non-face-to-face treatment and the implementation plan submitted by the Ministry of Health and Welfare.

 

The screening, which began at 9:30 a.m., is expected to continue until lunchtime.

 

The non-face-to-face treatment bill submitted by the Ministry of Health and Welfare is the main point of the pilot project currently being implemented.

 

It is a content that allows non-face-to-face treatment mainly for returning patients and clinics and allows first visits only in special cases such as residents of medically underserved areas, people with mobility difficulties, and people with disabilities.

 

Prescription drug delivery is allowed only in special cases by designating it as a home recipient, and basically, it is required to visit a pharmacy and receive face-to-face medication instruction.

 

However, the Ministry of Health and Welfare submitted an improved opinion on the regulation of non-face-to-face treatment platforms such as Dr.

 

Now.

 

First of all, platforms that want to run a non-face-to-face treatment brokerage business must go through a reporting process that requires government repairs.

 

In the case of non-reporting or false reporting, a fine of not more than 3 million won was imposed.

 

According to the Ministry of Health and Welfare, a report requiring repair is a report system operated with a relaxed permit.

 

It is not simply a report that meets formal requirements, but it must meet practical requirements such as human standards and material standards.

 

The report review by the Ministry of Health and Welfare also includes not only a formal review but also a substantive review on whether or not the statutory requirements or legislative purpose are met.

 

The view of multiple welfare committee members is that the key to reviewing the non-face-to-face treatment bill will be whether the Ministry of Health and Welfare has prepared specific countermeasures for the side effects that occurred during the pilot project.

 

The purpose is that legislation may be difficult if it is not clear how to manage the ratio of non-face-to-face treatment, which is focused on prescriptions for non-insured high-risk drugs such as hair loss treatments, morning-after pills, and acne medications.

 

In addition, it is expected that the Ministry of Health and Welfare will have to come up with solutions for electronic prescriptions issued after non-face-to-face treatment, such as managing sensitive patient information and preventing concerns about forgery.

 

In particular, the range of non-face-to-face treatment patients allowed in the pilot project stage is also a legislative issue.

 

The current pilot project permits all diseases other than those requiring a prescription for narcotic drugs or medicines concerned with misuse or abuse during non-face-to-face treatment other than first visits.

 

For this reason, there are criticisms that the side effects of non-face-to-face treatment, such as hair loss pills, morning-after pills, and acne medicine, are accelerating, such as the concentration of prescriptions in some treatment categories or disease groups.

 

Some welfare committee members are expressing the opinion that legislating such a pilot project as it is is too broad.

 

It is the opinion that non-face-to-face treatment should be allowed locally only for residents of medically vulnerable areas where non-face-to-face treatment is unavoidable due to poor mobility or lack of medical institutions and pharmacies in the living radius.

 

Cho Won-joon, the senior expert on the matter, said, "We examine the non-face-to-face treatment bill submitted by the Ministry of Health and Welfare, but how to manage non-consensual and irrational non-face-to-face treatment prescription behavior, such as non-insured hair loss prescriptions that have not yet been proposed or are omitted from the agenda, and how to manage e-prescriptions.

 

The position of the Ministry of Health and Welfare will determine the success or failure of the legislation,” he explained.

 

Commissioner Cho Won-joon explained, "The Ministry of Health and Welfare must clearly present a policy to operate the system so that non-face-to-face treatment does not produce side effects that threaten the safety of the public and patients and destroy the health care ecosystem."